<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124212</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02052</org_study_id>
    <nct_id>NCT03124212</nct_id>
  </id_info>
  <brief_title>Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland</brief_title>
  <acronym>CASCADE</acronym>
  <official_title>Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Basel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly
      diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually.
      Several hundred of these patients are likely to carry known genetic mutations associated with
      HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer
      deaths through early identification and engagement in high-risk management care that involves
      intensive surveillance, chemoprevention and/or prophylactic surgery. However, current rates
      of genetic testing indicate that many Swiss mutation carriers and their family members do not
      use cancer genetic services (counseling and/or testing), either due to lack of coordination
      of care or due to lack of communication about the mutation among family members.

      Cascade screening identifies and tests family members of a known mutation carrier. It
      determines whether asymptomatic family members are carriers of the identified mutation and
      proposes management options to reduce harmful outcomes. Robust evidence of basic science and
      descriptive population-based studies in Switzerland support the necessity of cascade
      screening for HBOC and LS. However, translation of this knowledge into public health
      interventions is lacking.

      Specific Aims of the CASCADE study are:

        1. Survey Index Patients diagnosed with HBOC or LS from clinic-based genetic testing
           records and determine their cancer status and surveillance practices; needs for
           coordination of medical care; psychosocial needs; patient-provider and patient-family
           communication needs; quality of life; willingness to serve as advocates for cancer
           genetic services for blood relatives.

        2. Survey first- and second-degree relatives, and first cousins identified from pedigrees
           and/or family history records of HBOC and LS Index Patients and determine their cancer
           and mutation status; cancer surveillance practices; needs for coordination of medical
           care; barriers and facilitators to using cancer genetic services; psychosocial needs;
           patient-provider and patient-family communication needs; quality of life; willingness to
           participate in a study designed to increase use of cancer genetic services.

        3. Explore the influence of patient-provider communication about genetic cancer risk on
           patient-family communication and the acceptability of a family-based communication,
           coping, and decision support intervention with focus group(s) of mutation carriers and
           blood relatives.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establishing the CASCADE Cohort</measure>
    <time_frame>12 months</time_frame>
    <description>Response rate for Index Patients with HBOC and LS and blood relatives</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Physical and mental quality of life of Index Patients and Blood Relatives</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Surveillance</measure>
    <time_frame>12 months</time_frame>
    <description>Number of mammograms, CBEs and MRIs of Index Patients and Blood Relatives</description>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Hereditary Breast and Ovarian Cancer</condition>
  <condition>Lynch Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CASCADE genetic screening</intervention_name>
    <description>Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Living carriers of pathogenic mutations associated with HBOC and LS, and their blood
        relatives (first- and second-degree, and first cousins)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Carrier of a mutation associated with HBOC or LS

          2. Have at least one living blood relative

          3. Men and women

          4. 18 years old and older

          5. Mentally and physically able to provide informed consent

          6. Can read and speak German or French or Italian or English

          7. Currently living in Switzerland.

        Exclusion Criteria:

          1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2,
             EPCAM genes

          2. Not living in Switzerland

          3. Patients who are critically ill and cannot complete the CASCADE survey

          4. Participants who are institutionalized (e.g., nursing homes) or incarcerated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria C Katapodi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria C Katapodi, PhD</last_name>
    <phone>++41791095163</phone>
    <email>maria.katapodi@unibas.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Heinimann, PhD</last_name>
      <phone>++41612653654</phone>
      <email>Karl.Heinimann@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Burki, MD</last_name>
      <phone>++41615565883</phone>
      <email>nicole.buerki@aeschenpraxis.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Viola Heinzelmann-Schwarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl Heinimann, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Burki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Kurzeder, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Zvizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6962</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivia Pagani, MD</last_name>
      <phone>++918118435</phone>
      <email>olivia.pagani@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Rossella Graffeo, MD</last_name>
      <phone>++918118435</phone>
      <email>Rossella.GraffeoGalbiati@eoc.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Olivia Pagani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rossella Graffeo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bauch- und Tumorzentrum der Universitatsklinik fur Viszerale Chirurgie und Medicine, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>2010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik C Horvath, PhD</last_name>
      <phone>++41316325900</phone>
      <email>Henrik.Horvath@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Henrik C Horvath, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatklinik fur Medizinische Onkologie, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuela Rabaglio, MD</last_name>
      <phone>++41316324370</phone>
      <email>Manuela.Rabaglio@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Rosmarie Buhrer, MSN</last_name>
      <phone>++41316325944</phone>
      <email>Rosmarie.Buehrer@insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Manuela Rabaglio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unite d'Oncogenetique et de Prevention des Cancers</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Chappuis, MD, PhD</last_name>
      <phone>++41223729853</phone>
      <email>Pierre.Chappuis@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Valeria Viassolo, MD</last_name>
      <phone>++41223729853</phone>
      <email>Valeria.Viassolo@hcuge.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre O Chappuis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeria Viassolo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>Maria Katapodi</investigator_full_name>
    <investigator_title>Professor of Nursing Science</investigator_title>
  </responsible_party>
  <keyword>mutation carrier</keyword>
  <keyword>blood relative</keyword>
  <keyword>genetic testing</keyword>
  <keyword>family-based cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon request, including purpose and expected timeline, anonymized patient data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

